Novel therapeutic Strategies for Targeting Liver Cancer Stem Cells
暂无分享,去创建一个
[1] Jean S. Campbell,et al. Liver regeneration. , 2012, Journal of hepatology.
[2] M. Makuuchi,et al. Recurrence‐free survival more than 10 years after liver resection for hepatocellular carcinoma , 2011, The British journal of surgery.
[3] Yunfang Wang,et al. Human hepatic stem cell and maturational liver lineage biology , 2011, Hepatology.
[4] M. Katoh. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. , 2011, Current pharmaceutical biotechnology.
[5] M. Parola,et al. Stem and progenitor cells in liver regeneration and repair. , 2011, Cytotherapy.
[6] N. Fausto,et al. New concepts in liver regeneration , 2011, Journal of gastroenterology and hepatology.
[7] L. Nicholson,et al. Cancer stem cells: problems for therapy? , 2011, The Journal of pathology.
[8] I. Ng,et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. , 2010, Cell stem cell.
[9] Yong Zeng,et al. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.
[10] J. Luk,et al. Activation of interleukin‐6–induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[11] Elizabeth G. Loboa,et al. Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver fates , 2010, Hepatology.
[12] A. Zhu,et al. The role of signaling pathways in the development and treatment of hepatocellular carcinoma , 2010, Oncogene.
[13] Y. Jeng,et al. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. , 2010, Carcinogenesis.
[14] K. Mimori,et al. CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.
[15] A. Iwama,et al. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf‐dependent and ‐independent manners in Mice , 2010, Hepatology.
[16] O. Rosmorduc,et al. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. , 2010, Seminars in liver disease.
[17] A. Kazlauskas. Faculty Opinions recommendation of An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. , 2010 .
[18] Wenbo Zhou,et al. Expression of Oct4 in HCC and modulation to wnt/β-catenin and TGF-β signal pathways , 2010, Molecular and Cellular Biochemistry.
[19] A. Krešo,et al. Cancer Stem Cells and Self-renewal , 2010, Clinical Cancer Research.
[20] Yonghe Li,et al. Dkk1 Stabilizes Wnt Co-Receptor LRP6: Implication for Wnt Ligand-Induced LRP6 Down-Regulation , 2010, PloS one.
[21] M. Honda,et al. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. , 2010, Cancer research.
[22] O. Gires,et al. EpCAM as a target in cancer therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Dufour,et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside , 2010, Expert opinion on biological therapy.
[24] W. Xie,et al. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta‐analysis , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[25] M. Bhatia,et al. Novel roles for Notch, Wnt and Hedgehog in hematopoesis derived from human pluripotent stem cells. , 2010, The International journal of developmental biology.
[26] Kathleen M Kokolus,et al. Non-canonical Wnt signaling pathways in hematopoiesis , 2010, Immunologic research.
[27] C. Cavard,et al. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. , 2010, Journal of hepatology.
[28] K. Choy,et al. MiR-222 Overexpression Confers Cell Migratory Advantages in Hepatocellular Carcinoma through Enhancing AKT Signaling , 2010, Clinical Cancer Research.
[29] Zhao-You Tang,et al. Influence of hepatic artery occlusion on tumor growth and metastatic potential in a human orthotopic hepatoma nude mouse model: Relevance of epithelial–mesenchymal transition , 2010, Cancer science.
[30] S. Lowe,et al. miR-221 overexpression contributes to liver tumorigenesis , 2009, Proceedings of the National Academy of Sciences.
[31] Kevin Struhl,et al. An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation , 2009, Cell.
[32] D. Schuppan,et al. Pharmacological inhibition of integrin αvβ3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis , 2009, Hepatology.
[33] M. Petz,et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. , 2009, Future oncology.
[34] S. Thorgeirsson,et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties , 2009, Oncogene.
[35] Marc W. Kirschner,et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.
[36] L. Mishra,et al. Cancer stem cells and hepatocellular carcinoma , 2009, Cancer biology & therapy.
[37] M. Manns,et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.
[38] T. Ikegami. Transforming growth factor‐β signaling and liver cancer stem cell , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.
[39] Jianren Gu,et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma , 2009, International journal of cancer.
[40] X. Wang,et al. Identification of microRNA‐181 by genome‐wide screening as a critical player in EpCAM–positive hepatic cancer stem cells , 2009, Hepatology.
[41] I. Ng,et al. Liver cancer stem cells: implications for a new therapeutic target , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[42] Markus Munz,et al. The emerging role of EpCAM in cancer and stem cell signaling. , 2009, Cancer research.
[43] Marcus Fruttiger,et al. The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis , 2009, Cell.
[44] Zhen Fan Yang,et al. An Akt/Hypoxia-Inducible Factor-1α/Platelet-Derived Growth Factor-BB Autocrine Loop Mediates Hypoxia-Induced Chemoresistance in Liver Cancer Cells and Tumorigenic Hepatic Progenitor Cells , 2009, Clinical Cancer Research.
[45] Zhengxin Wang,et al. Notch1 Signaling Sensitizes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Hepatocellular Carcinoma Cells by Inhibiting Akt/Hdm2-mediated p53 Degradation and Up-regulating p53-dependent DR5 Expression* , 2009, The Journal of Biological Chemistry.
[46] H. Bellen,et al. A Notch updated , 2009, The Journal of cell biology.
[47] Michael A. Beer,et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation , 2009, Proceedings of the National Academy of Sciences.
[48] X. Wang,et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.
[49] Jeffrey S. Morris,et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Brigitte Mack,et al. Nuclear signalling by tumour-associated antigen EpCAM , 2009, Nature Cell Biology.
[51] B. Stiles,et al. Expansion of CD133‐Expressing Liver Cancer Stem Cells in Liver‐Specific Phosphatase and Tensin Homolog Deleted on Chromosome 10‐Deleted Mice , 2009, Stem cells.
[52] M. Eichenmüller,et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth , 2009, Hepatology.
[53] Yun Yen,et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer , 2009, Cancer Chemotherapy and Pharmacology.
[54] Yu Wei,et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. , 2008, Cancer cell.
[55] Jun-Ping Zhang,et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor‐4α gene , 2008, Hepatology.
[56] A. Iwama,et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. , 2008, Cancer research.
[57] P. Pollock,et al. Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.
[58] K. Schulze-Osthoff,et al. Cancer stem cell markers in common cancers - therapeutic implications. , 2008, Trends in molecular medicine.
[59] L. Mishra,et al. Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis , 2008, Hepatology.
[60] Qiyu Wang,et al. Down-regulation of Sonic hedgehog signaling pathway activity is involved in 5-fluorouracil-induced apoptosis and motility inhibition in Hep3B cells. , 2008, Acta biochimica et biophysica Sinica.
[61] H. Li,et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma , 2008, International journal of clinical practice.
[62] L. Mishra,et al. Liver stem cells and tgf-Beta in hepatic carcinogenesis. , 2008, Gastrointestinal cancer research : GCR.
[63] M. Krause,et al. Exploring the role of cancer stem cells in radioresistance , 2008, Nature Reviews Cancer.
[64] Nathalie Wong,et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. , 2008, Gastroenterology.
[65] Y. Nakanuma,et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma , 2008, Laboratory Investigation.
[66] Shinya Yamanaka,et al. Pluripotency and nuclear reprogramming , 2008, Philosophical Transactions of the Royal Society B: Biological Sciences.
[67] S. Rafii,et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] P. Carter,et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers , 2008, British Journal of Cancer.
[69] Liang Tang,et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. , 2008, Cancer research.
[70] H. Horinouchi,et al. Enhanced radiation response of a solid tumor with the artificial oxygen carrier ‘albumin‐heme’ , 2008, Cancer science.
[71] G. Daley,et al. Selective Blockade of MicroRNA Processing by Lin28 , 2008, Science.
[72] B. Han,et al. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.
[73] X. Guan,et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway , 2008, Oncogene.
[74] Krista A. Zanetti,et al. Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.
[75] Jin Woo Kim,et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.
[76] J. Fargnoli,et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) , 2008, Journal of medicinal chemistry.
[77] C. Deng,et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling , 2008, Proceedings of the National Academy of Sciences.
[78] Yu Chen,et al. Deregulated expression of Notch receptors in human hepatocellular carcinoma. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[79] F. Zhang,et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double‐fluorescence immunostaining evidence , 2007, Histopathology.
[80] Xin Wei Wang,et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.
[81] B. Cieply,et al. siRNA-Mediated β-Catenin Knockdown in Human Hepatoma Cells Results in Decreased Growth and Survival* , 2007 .
[82] A. Iwama,et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. , 2007, Gastroenterology.
[83] L. Bolondi,et al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[84] Nancy Cheng,et al. Human hepatic stem cells from fetal and postnatal donors , 2007 .
[85] M. Matsuda,et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin , 2007, Hepatology.
[86] Xiong-Zhi Wu,et al. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma , 2007, Journal of gastroenterology and hepatology.
[87] J. Drevs,et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] M. Katoh,et al. WNT Signaling Pathway and Stem Cell Signaling Network , 2007, Clinical Cancer Research.
[89] I. Ng,et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.
[90] Arndt F. Siekmann,et al. Notch Signalling and the Regulation of Angiogenesis , 2007, Cell adhesion & migration.
[91] Jianren Gu,et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity , 2007, International journal of cancer.
[92] L. Chow,et al. Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] C. Rogler,et al. Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver , 2007, Hepatology.
[94] Antonio Duarte,et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching , 2007, Proceedings of the National Academy of Sciences.
[95] W. Alexander,et al. Opposing roles of gp130‐mediated STAT‐3 and ERK‐1/2 signaling in liver progenitor cell migration and proliferation , 2007, Hepatology.
[96] Takahiro Kunisada,et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. , 2006, Biochemical and biophysical research communications.
[97] H. Aburatani,et al. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. , 2006, Gene.
[98] Franziska Michor,et al. Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.
[99] Laura Marelli,et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. , 2006, Cancer treatment reviews.
[100] Lin Chen,et al. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells. , 2006, Hepatobiliary & pancreatic diseases international : HBPD INT.
[101] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.
[102] S. Bray. Notch signalling: a simple pathway becomes complex , 2006, Nature Reviews Molecular Cell Biology.
[103] G. Gores,et al. Emerging drugs for hepatocellular carcinoma , 2006, Expert opinion on emerging drugs.
[104] Daniel J. Hoeppner,et al. Notch signalling regulates stem cell numbers in vitro and in vivo , 2006, Nature.
[105] M. Ratain,et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.
[106] E. Lesaffre,et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.
[107] S. Johnston,et al. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. , 2006, Drugs of today.
[108] Tetsuhiro Chiba,et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties , 2006, Hepatology.
[109] A. Zhu. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? , 2006, The oncologist.
[110] Qian Wang,et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. , 2006, Carcinogenesis.
[111] S. Forbes,et al. Side population (SP) cells: Taking center stage in regeneration and liver cancer? , 2006, Hepatology.
[112] P. Schirmacher,et al. Dysregulation of growth factor signaling in human hepatocellular carcinoma , 2006, Oncogene.
[113] T. Roskams. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma , 2006, Oncogene.
[114] M. Kuwano,et al. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. , 2006, Cancer research.
[115] J. Wands,et al. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma , 2006, Hepatology.
[116] J. Olynyk,et al. Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo , 2006, Hepatology.
[117] L. Bolondi,et al. Notch3 intracellular domain accumulates in HepG2 cell line. , 2006, Anticancer research.
[118] J. Sicklick,et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. , 2006, Carcinogenesis.
[119] M. Santoro,et al. BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.
[120] M. Oertel,et al. Liver stem cells and prospects for liver reconstitution by transplanted cells , 2006, Hepatology.
[121] Y. Murawaki,et al. Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells , 2006, Journal of Gastroenterology.
[122] M. Alison,et al. Liver cancer: the role of stem cells , 2005, Cell proliferation.
[123] H. Axelson,et al. Regulation of the Notch target gene Hes-1 by TGFalpha induced Ras/MAPK signaling in human neuroblastoma cells. , 2005, Experimental cell research.
[124] D. Schuppan,et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. , 2005, Journal of hepatology.
[125] F. E. Bertrand,et al. Increased Protein Expression of the PTEN Tumor Suppressor in the Presence of Constitutively Active Notch-1 , 2005, Cell cycle.
[126] Elaine Fuchs,et al. Asymmetric cell divisions promote stratification and differentiation of mammalian skin , 2005, Nature.
[127] K. Katano,et al. The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. , 2005, Journal of experimental & clinical cancer research : CR.
[128] Randall T. Moon,et al. Wnt and calcium signaling: β-Catenin-independent pathways , 2005 .
[129] A. Donnenberg,et al. Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis , 2005, Journal of clinical pharmacology.
[130] G. Morgan,et al. Dose‐ and time‐dependent oval cell reaction in acetaminophen‐induced murine liver injury , 2005, Hepatology.
[131] S. Barry,et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.
[132] K. Glaser,et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor , 2005, Molecular Cancer Therapeutics.
[133] S. Kubo,et al. Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell: Immunohistochemical evidence. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.
[134] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[135] B. Gao,et al. Cytokines, STATs and liver disease. , 2005, Cellular & molecular immunology.
[136] W. Park,et al. Mutations of β‐catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[137] D. Schuppan,et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. , 2004, Journal of hepatology.
[138] J. Dufour,et al. Angiogenesis and hepatocellular carcinoma. , 2004, Journal of hepatology.
[139] R. Nusse,et al. The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.
[140] Miran Kim,et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. , 2004, Gastroenterology.
[141] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[142] P. Schirmacher,et al. Factors of transforming growth factor β signalling are co-regulated in human hepatocellular carcinoma , 2004, Virchows Archiv.
[143] M. Goodell,et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[144] M. Lohuizen,et al. Stem Cells and Cancer The Polycomb Connection , 2004, Cell.
[145] Lawrence Lum,et al. The Hedgehog Response Network: Sensors, Switches, and Routers , 2004, Science.
[146] N. Fausto. Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells , 2004, Hepatology.
[147] T. Kurihara,et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. , 2004, International journal of oncology.
[148] M. Lohuizen,et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas , 2004, Nature.
[149] X. Wang,et al. Cancer‐associated molecular signature in the tissue samples of patients with cirrhosis , 2004, Hepatology.
[150] J. Aster,et al. Multiple niches for Notch in cancer: context is everything. , 2004, Current opinion in genetics & development.
[151] T. Roskams,et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease , 2004, Hepatology.
[152] B. Chauffert,et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.
[153] Xuetao Cao,et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. , 2003, Cancer research.
[154] J. Folkman,et al. Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.
[155] B. Portmann,et al. Hepatic ‘stem cell’ malignancies in adults: four cases , 2003, Histopathology.
[156] A. West,et al. Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. , 2003, Journal of hepatology.
[157] Manuel Hidalgo,et al. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.
[158] Hans Clevers,et al. Caught up in a Wnt storm: Wnt signaling in cancer. , 2003, Biochimica et biophysica acta.
[159] Hiroaki Sakurai,et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. , 2003, Molecular cancer therapeutics.
[160] Irving L. Weissman,et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells , 2003, Nature.
[161] M. Joo,et al. Expression of beta-catenin in hepatocellular carcinoma in relation to tumor cell proliferation and cyclin D1 expression. , 2003, Journal of Korean medical science.
[162] C. Deng,et al. Disruption of Transforming Growth Factor-β Signaling in ELF β-Spectrin-Deficient Mice , 2003, Science.
[163] M. Matzuk,et al. Genetic Analysis of the Mammalian Transforming Growth Factor-β Superfamily , 2002 .
[164] A. Zimmermann. Hepatoblastoma with cholangioblastic features ('cholangioblastic hepatoblastoma') and other liver tumors with bimodal differentiation in young patients. , 2002, Medical and pediatric oncology.
[165] T. Elliott,et al. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens , 2002, European journal of immunology.
[166] R. Nusse,et al. Ligand Receptor Interactions in the Wnt Signaling Pathway inDrosophila * , 2002, The Journal of Biological Chemistry.
[167] Yina Li,et al. Shh and Gli3 are dispensable for limb skeleton formation but regulate digit number and identity , 2002, Nature.
[168] David I. Smith,et al. Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas , 2002, Oncogene.
[169] M. Kühl. Non-canonical Wnt signaling in Xenopus: regulation of axis formation and gastrulation. , 2002, Seminars in cell & developmental biology.
[170] T. Pieler,et al. Gli-type zinc finger proteins as bipotential transducers of Hedgehog signaling. , 2002, Differentiation; research in biological diversity.
[171] J. Shimazaki,et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[172] Robert L Davis,et al. Vertebrate hairy and Enhancer of split related proteins: transcriptional repressors regulating cellular differentiation and embryonic patterning , 2001, Oncogene.
[173] P. Ingham,et al. Hedgehog signaling in animal development: paradigms and principles. , 2001, Genes & development.
[174] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[175] H. Nakauchi,et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.
[176] G. Thomas,et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.
[177] William I. Weis,et al. The Structure of the β-Catenin/E-Cadherin Complex and the Molecular Basis of Diverse Ligand Recognition by β-Catenin , 2001, Cell.
[178] Y. Chung,et al. Expression of Transforming Growth Factor beta-1 in Chronic Hepatitis and Hepatocellular Carcinoma Associated with Hepatitis C Virus Infection , 2000, The Korean journal of internal medicine.
[179] P. Iannaccone,et al. The sonic hedgehog-patched-gli pathway in human development and disease. , 2000, American journal of human genetics.
[180] P. Leder,et al. Ras pathway signals are required for notch-mediated oncogenesis , 2000, Oncogene.
[181] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[182] Yusuke Nakamura,et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.
[183] Philip A Beachy,et al. Hedgehog-Regulated Processing of Gli3 Produces an Anterior/Posterior Repressor Gradient in the Developing Vertebrate Limb , 2000, Cell.
[184] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[185] T. Kornberg,et al. Ci: a complex transducer of the hedgehog signal. , 1999, Trends in genetics : TIG.
[186] M. Ozturk,et al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma , 1999, Oncogene.
[187] S. Artavanis-Tsakonas,et al. Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .
[188] William J. Ray,et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.
[189] Yasunori Tanaka,et al. Sonic Hedgehog-induced Activation of the Gli1Promoter Is Mediated by GLI3* , 1999, The Journal of Biological Chemistry.
[190] J. Mulé,et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[191] H. Friess,et al. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. , 1999, American journal of surgery.
[192] J. Olynyk,et al. Oval cell numbers in human chronic liver diseases are directly related to disease severity. , 1999, The American journal of pathology.
[193] B. Geiger,et al. Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. , 1998, Current opinion in cell biology.
[194] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[195] M. Noll,et al. Hedgehog and its patched-smoothened receptor complex: a novel signalling mechanism at the cell surface. , 1997, Biological chemistry.
[196] S. Sell,et al. Heterogeneity of the "oval-cell" response in the hamster liver during cholangiocarcinogenesis following Clonorchis sinensis infection and dimethylnitrosamine treatment. , 1997, Journal of hepatology.
[197] V. Ambros,et al. The Cold Shock Domain Protein LIN-28 Controls Developmental Timing in C. elegans and Is Regulated by the lin-4 RNA , 1997, Cell.
[198] M. Colombo,et al. Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.
[199] P. Bedossa,et al. Transforming growth factor—beta 1 (TGF‐β1) and TGF‐β1 receptors in normal, cirrhotic, and neoplastic human livers , 1995, Hepatology.
[200] J. Hooper. Distinct pathways for autocrine and paracrine Wingless signalling inDrosophila embryos , 1994, Nature.
[201] F. Oesch,et al. Oval cell lines OC/CDE 6 and OC/CDE 22 give rise to cholangio-cellular and undifferentiated carcinomas after transformation. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[202] S. Artavanis-Tsakonas,et al. Modulation of wingless signaling by Notch in Drosophila , 1994, Mechanisms of Development.
[203] P. Holst,et al. Hepatic Progenitor Populations in Embryonic, Neonatal, and Adult Liver 1 , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[204] H. Horvitz,et al. Heterochronic mutants of the nematode Caenorhabditis elegans. , 1984, Science.
[205] J. W. Steiner,et al. Cell population dynamics in the liver. A review of quantitative morphological techniques applied to the study of physiological and pathological growth. , 1966, Experimental and molecular pathology.
[206] S. Cheung,et al. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. , 2011, Gastroenterology.
[207] Lee F. Peng,et al. Small-molecule modulators of the Sonic Hedgehog signaling pathway. , 2010, Molecular bioSystems.
[208] N. Kobayashi,et al. Hepatic stem cells and liver development. , 2010, Methods in molecular biology.
[209] X. Guan,et al. miR-130b is preferentially upregulated in CD133+ liver cancer stem cells and regulates tumor growth and self-renewal via tumor protein 53-induced nuclear protein 1 , 2009 .
[210] M. Kao,et al. Differential expression of Sonic hedgehog and Gli1 in hematological malignancies , 2008, Leukemia.
[211] M. Alison. Liver stem cells , 2007, Stem Cell Reviews.
[212] P. Marynen,et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. , 2006, Blood.
[213] S. Wilhelm,et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.
[214] S. Vowler,et al. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. , 2005, Gastroenterology.
[215] Randall T Moon,et al. Wnt and calcium signaling: beta-catenin-independent pathways. , 2005, Cell calcium.
[216] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.
[217] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .
[218] Juthamas Sukbuntherng,et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[219] Andrew P McMahon,et al. Developmental roles and clinical significance of hedgehog signaling. , 2003, Current topics in developmental biology.
[220] C. Deng,et al. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. , 2003, Science.
[221] M. Matzuk,et al. Genetic analysis of the mammalian transforming growth factor-beta superfamily. , 2002, Endocrine reviews.
[222] W. Weis,et al. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. , 2001, Cell.
[223] J. Massagué,et al. TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.
[224] J. Whangbo,et al. A Wnt signaling pathway controls hox gene expression and neuroblast migration in C. elegans. , 1999, Development.
[225] J. Tsai,et al. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. , 1997, British Journal of Cancer.
[226] P. Bedossa,et al. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. , 1995, Hepatology.